Aspirin and Preeclampsia
ConditionPreeclampsia Postpartum
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-45
SponsorUniversity of Chicago
About this trial
This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.
Eligibility criteria
Qualifiers
Pregnant Adults between 18 and 45 years of age
Diagnosed with preeclampsia
Presenting for delivery with a singleton gestation.
Disqualifiers
We will exclude patients in labor
Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation
Plan to deliver outside of the participating site
Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.
Trial design
Treatments tested in this trial
- Aspirin 81 mg
- Placebo
Treatment groups
180 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov